Evidence map›Paper›PMID 40964713›Full record

ReviewExpert opinion on therapeutic targets2025

Identifying protease-activated targets and exploring therapeutic applications.

Deokhee Kang, Charles S Craik

Abstract readReview
In one paragraph

Review in Expert opinion on therapeutic targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Deokhee KangDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.ORCID 0000-0002-2241-0751
Charles S CraikDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.ORCID 0000-0001-7704-9185

Funding

Precision targeting of T cell cytotoxicity with PETR01CA258297 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AGGARWAL, RAHUL, CRAIK, CHARLES SCOTT · 2021 to 2025
$3.1M
New radiotracer development to study immune cell mobilization of granzyme proteolytic activityR01AI161027 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIK, CHARLES SCOTT, EVANS, MICHAEL JOHN · 2021 to 2024
$2.8M
NCI NIH HHS R01 CA258297NIAID NIH HHS R01 AI161027
6 · The paper itself

Abstract

introductionProteases are essential enzymes that regulate protein turnover and activate signaling pathways through targeted peptide bond cleavage. While traditionally regarded as degradative agents, proteases are now recognized for their diverse roles in health and disease, particularly in cancer and viral infections. Advances in high-throughput, mass spectrometry-based technologies have enabled proteome-wide identification of protease substrates, revealing numerous potential therapeutic targets. As large-scale approaches yield expansive substrate lists, it is increasingly important to understand the roles of disease-related proteases within their specific biological contexts. AREAS COVERED: Peptide-level chemical libraries have provided more practical insights, facilitating the development of protease-targeted interventions. However, early efforts to derive inhibitors from these substrates faced challenges due to enzymatic redundancy and substrate promiscuity. Consequently, emerging research has shifted toward harnessing proteolytic activity for conditional activation of therapeutics. Since proteolytic activation can amplify therapeutic effects, protease-activated strategies, such as protease-cleavable linkers in antibody-drug conjugates, have gained interest and are now being applied to other therapeutic modalities. EXPERT OPINION: We believe that identifying substrates activated by disease-associated proteases, enabled by recent technological advances, will lead to deeper biological insights. When combined with peptide-level techniques, these discoveries can drive the development of efficient therapeutic interventions with amplified effects.

Indexed as

Drug DevelopmentMolecular Targeted TherapyPeptide HydrolasesAnimalsHigh-Throughput Screening AssaysHumansImmunoconjugatesMass SpectrometryNeoplasmsPeptide LibraryProteolysisSignal TransductionImmunoconjugatesPeptide HydrolasesPeptide LibraryCancer therapeuticsconditional activationendogenous substratesmass spectrometrypeptide substrate profilingProdrugsProteasestumor microenvironment

Identifiers

PMID40964713
PMCPMC12533553

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.